First covid Nasal vaccine by Bharat Biotech gets permission for clinical trials in India
Bharat Biotech's intranasal vaccine has obtained regulatory clearance for Phase 2/3 studies, as part of continuing research across the globe to produce nasal sprays to help prevent coronavirus illness (Covid-19). The adenoviral intranasal vaccine BBV154 is the first Covid-19 shot of its type to be tested in humans in India. According to the Ministry of Science and Technology, the Phase 1 study in healthy participants aged 18 to 60 years was well tolerated. Bharat Biotech's intranasal vaccine development has been funded by the Department of Biotechnology (DBT) and the Biotechnology Industry Research Assistance Council (BIRAC).